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Highlights 
 
 Drug induced liver injury is a major reason for compound drop-out during drug 
development. 
 
 Xenopus embryos provide a useful in vivo model to study drug toxicity. 
 
 Xenopus embryos exhibit similar reactions to paracetamol induced liver injury 
observed in mammalian models. 
 
Astract 
Introduction: Failure to predict drug-induced liver injury (DILI) remains a major 
contributing factor to lead compound drop-out during drug development. Xenopus 
embryos are amenable for early stage medium throughput small molecule screens and 
so have the potential to be used in pre-clinical screens. To begin to assess the 
usefulness and limitations of Xenopus embryos for safety assessment in the early 
phases of drug development, paracetamol was used as a model hepatotoxin. 
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Paracetamol overdose is associated with acute liver injury. In mammals, the main 
mechanism of paracetamol-induced acute liver injury is an increased amount of the 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) combined with a 
reduction of free glutathione (GSH). Humans that have taken an overdose of 
paracetamol are often treated with N-acetyl cysteine (NAC). 
Method: Xenopus laevis embryos were treated with up to 5 mM paracetamol from 
stage 38 to stage 45 during development, when the liver is functional. The presence 
of paracetamol-induced liver injury was assessed by: (1) microRNA-122 (miR-122) 
expression (a hepatic marker), (2) free GSH concentration (a marker of oxidative 
stress) and (3) NAC antioxidant intervention.  
Results: The amount of free GSH decreased significantly in embryos exposed to 
increasing paracetamol concentration. In embryos exposed to 5 mM paracetamol, 
22.574.25 nmol/mg GSH was detected compared to 47.117.31 nmol/mg untreated 
embryos (meanSEM). In tail tissue, miRNA-122 expression increased 6.3-fold with 3 
mM paracetamol concentration treatment compared to untreated embryos. NAC 
treatment altered the free GSH decline for embryos treated with up to 5 mM. Embryos 
exposed to 1 mM paracetamol and then exposed to 0.5 mM  NAC 24h prior to harvest, 
had an significantly higher amount GSH compared to embryos that were only exposed 
to 1 mM paracetamol (meanSEM; 97.19.6 nmol/mg and 54.56.6 nmol/mg 
respectively). 
Conclusion: Xenopus laevis embryos exhibit similar characteristics of paracetamol-
induced liver injury observed in mammalian models. These data indicate that the 
Xenopus embryo could be a useful in vivo model to assess DILI and aid lead 
compound prioritisation during the early phase of drug development, in combination 
with pre-clinical in vitro studies. Consequently, the Xenopus embryo could contribute 
to the reduction principle as defined by the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research. 
Keywords:  
Xenopus laevis; Drug-induced liver injury (DILI); paracetamol; pre-clinical studies 
 
Introduction 
Paracetamol is a frequently used antipyretic and analgesic drug that is safe at the 
therapeutic dose, which is 4 g/day. However, it exhibits dose-dependent hepatotoxicity 
and severe liver injury can occur when a single dose of 10-15 g of paracetamol is taken 
(1,2). Paracetamol contributes to 80 % of the liver failure cases associated with drugs 
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(3). It is the single largest cause of acute liver failure in the US and the UK and the 
second most common reason for a liver transplant (4). In the UK, it is estimated 
approximately 90000 patients present with paracetamol overdose a year, resulting in 
50000 hospital admissions and 150-250 deaths (5–7). The paracetamol reactive 
metabolite that is responsible for paracetamol-induced liver injury is N-acetyl-p 
benzoquinone imine (NAPQI). When a paracetamol overdose has been taken, the 
supply of cellular glutathione (GSH) is saturated and therefore less NAPQI is 
neutralised. In hepatocytes, NAPQI can form protein adducts with intracellular 
proteins, which can lead to mitochondrial dysfunction, nuclear DNA fragmentation, 
oxidative stress, hepatocyte death and subsequent acute liver failure, and potentially 
patient death (8,9). The major cell death pathway is necrotic, although some apoptotic 
cell death can also occur.  
Xenopus laevis (the African clawed frog) can produce approximately 1000 
embryos/day with hormonal stimulation. Following in vitro fertilisation, the embryos 
rapidly develop ex utero and are amenable for medium throughput small molecule 
screens. As part of these screens, it was noted that Xenopus embryos could highlight 
compound toxicity (10–12). Consequently, as well as being useful to identify new 
drugs, Xenopus embryos may also represent a model for early phase pre-clinical drug 
toxicity studies during drug development. Previously, we have successfully used this 
model to help assess nanotoxicity for biomedically-relevant nanomaterials (13). 
The Xenopus embryo shares similar advantages to another non-mammalian animal 
model, the zebrafish (Danio rerio) (14). They are both easier to house and less 
expensive than mammalian animal models. However, unlike in zebrafish, not much 
work has been done to investigate the use of Xenopus embryos for the prediction of 
drug-induced toxicity.  
Drug-induced liver injury (DILI) was investigated in order to begin to characterise the 
use of Xenopus embryos as a predictive tool for drug-induced toxicity. Paracetamol 
was used as the model hepatotoxin. Paracetamol-induced liver injury is dose-
dependent. Therefore it was hypothesised that the Xenopus laevis embryos would 
exhibit indications of paracetamol-induced liver injury that correlated with paracetamol 
dose exposure. Increasing paracetamol concentration exposure to the Xenopus 
embryos, correlated with an increased expression of the liver-specific biomarker miR-
122 in tissue that does not include the liver, and a depletion of free GSH.  
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Results 
Paracetamol exposure response in Xenopus laevis embryos 
Stage 38 Xenopus laevis embryos were exposed to paracetamol that was dissolved 
into the embryo incubation media. After a 72 h incubation period, the resulting stage 
45 embryos showed a variety of phenotypes (Figure 1). Untreated stage 45 Xenopus 
embryos were termed “wildtype”. In the treatment group, the wildtype phenotype was 
less common with increasing paracetamol concentration. Of the embryos that were 
exposed to the Xenopus media only, 96% displayed a wildtype phenotype, which 
decreased to 24% for the embryos exposed to 5 mM paracetamol.  
Phenotypes that deviated from the norm included damaged tail, oedema, abnormal 
gut and bent tail (Figure 1A-E). The incidence of all phenotypes that are different to 
the wildtype was larger with increasing paracetamol concentration from 4% to 46%, 
Xenopus media only to 5 mM paracetamol exposure respectively (Figure 1F). 
Oedema typically occurred around the gastro-intestinal region of the embryo (Figure 
1C). The percentage of stage 38 embryos that were exposed to 5 mM paracetamol 
and did not survive to the harvest age of stage 45 was 9% compared to the 4% 
incidence for the embryos exposed to Xenopus media only. 
Free GSH content in Paracetamol Treated Embryos 
In humans, the generation of the reactive metabolite, NAPQI, and the reduction of the 
neutralising agent, GSH, mediate paracetamol-induced liver injury. Consequently, the 
amount of free GSH can indicate the metabolism pathway of paracetamol and be an 
indirect measurement of paracetamol-induced liver injury.  Existing in vivo or in vitro 
assays that imitate human paracetamol overdose and the associated acute liver 
failure, show a reduction of free GSH in the assay system (15–18). 
Embryos at stage 38 were treated with a paracetamol concentration within the range 
0-5 mM, harvested at stage 45, and processed to measure the amount of free GSH 
(n=10) (Figure 2). The amount of free GSH decreased from 47 nmol/mg to 22 nmol/mg 
with increasing concentration of paracetamol (0-5 mM). Embryos treated with a 
paracetamol concentration within the range 3-5 mM had statistically significantly less 
free GSH compared to untreated embryos (5 mM paracetamol exposure meanSEM 
was 22.574.25 nmol/mg compared to untreated meanSEM of 47.117.31 nmol/mg). 
Xenopus laevis embryos that are incubated at 23°C take 72h to develop from stage 38 
to stage 45. In order to explore the time-dependency of the decline in free GSH, stage 
38 embryos were treated with the same paracetamol concentration range (0-5 mM) 
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and harvested them after 24h, at stage 41 (Figure 2B). There was no significant 
change in the relationship between paracetamol treatment and amount of free GSH 
when the embryos are treated for 24h.  
miR-122 is a marker for the liver in Xenopus embryos 
The location of the liver is not always obvious in the Xenopus laevis embryo, it is <0.5 
mm at its widest diameter, and the colour of it is not notably different to the intestines. 
Thus, a probe was used to identify the liver using a wholemount in situ hybridisation 
(WISH) protocol. Alpha-1-microglobulin/bikunin precursor (AMBP) is a protein 
specifically expressed in the Xenopus liver (19) and so it was used as a positive control 
for the WISH. Stage 38 and stage 45 embryos expressed AMBP in the presumed 
location of the liver (Figure 3A) (n=10).  
The expression of miR-122 in the Xenopus embryos was investigated using the WISH 
assay (20) (Figure 3B) (n=10). MiR-122 expression is specific to the liver in humans 
as well as rodent and zebrafish animal models (21–23). Elevated miR-122 in the 
circulation can therefore serve as a biomarker for DILI (24). The miR-122 WISH probe 
has been extensively characterised in Xenopus previously (20). The WISH for miR-
122 stained the same area as AMBP in stage 38 and stage 45 embryos (Figure 3). 
Therefore, it was concluded that the miR-122 expression in Xenopus laevis is specific 
to the liver tissue, which is very similar to the expression seen in rodent, zebrafish and 
humans. 
The expression of miR-122 in the different tissues of embryos 
treated with paracetamol 
Stage 38 embryos were exposed to a paracetamol concentration within the range 0-5 
mM, harvested at stage 45 and then processed to measure the expression of miR-122 
using qRT-PCR. Embryos were dissected to obtain gut tissue that included the liver 
and tail tissue to represent the blood. The tail contains a good vasculature and the liver 
tissue is not present in this body compartment (Supplementary Figure 1). 
The miR-122 expression levels were normalised to a miRNA (miR-103), which has 
been shown to not be affected by paracetamol treatment in rodents (25). Similarly, the 
expression of miR-103 is not affected by paracetamol in Xenopus laevis 
(Supplementary Figure 2). The miR-122 expression was also normalised to 
untreated (Xenopus media only) embryos (Figure 4).  
The expression of miR-122 increased in the tail tissue with increasing paracetamol 
concentration. In untreated wildtype embryos, the miR-122 expression in the tail was 
minimal. miR-122 expression in the tail of embryos treated with 3 mM and 4 mM 
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paracetamol was significantly different compared with miR-122 expression in the gut 
tissue from the same paracetomol-treated embryos (Figure 4). Embryos treated with 
the 3 mM paracetamol concentration in particular, had a 6.3-fold (plotted as 0.8 on the 
logarithmic y-axis scale) increase in miR-122 expression in the tail, compared with the 
tail tissue of untreated embryos. In the gut tissue, the expression of miR-122 appears 
to be slightly reduced in treated embryos compared with untreated embryos, but miR-
122 expression does not change in relation to the paracetamol concentration, it 
remains level (Figure 4).  
Treatment with acetyl-meta-aminophenol (AMAP) 
AMAP is supposedly the non-toxic regioisomer version of APAP, but this appears to 
be species-dependent (26). The Xenopus response to AMAP was explored by looking 
at the effect of GSH depletion, which was determined by measuring the amount of free 
GSH in embryos from the same mother, treated with either AMAP or APAP in the same 
concentration range (0-5 mM, n=3). The embryos treated with AMAP produced a 
negative correlation: as the concentration of AMAP increased, the amount of free GSH 
detected decreased (Figure 5). The amount of GSH between embryos treated with 
the same concentration of either AMAP or APAP was not significantly different. 
Xenopus incubation with the human clinical treatment for 
paracetamol overdose 
In the clinic, patients are administered N-acetyl cysteine (NAC) to prevent severe 
paracetamol-induced liver injury. The NAC replenishes GSH stores, scavenges ROS 
in mitochondria and enhances the sulphation APAP metabolic pathway. The NAC 
therapeutic effect is more useful at preventing liver injury if it is taken less than 8 hours 
after the APAP overdose (27, 28). 
Xenopus embryos were co-incubated with 0.5 mM NAC and a concentration within the 
0-5 mM APAP range. Initially, NAC and APAP were co-incubated in 2 conditions: (1) 
incubation of the stage 38 embryos with 0.5 mM NAC for 2h and then the APAP 
concentration was added to the media and (2) concurrent 0.5 mM NAC and APAP 
(n=10) (Figure 6A). The embryos were harvested at stage 45 and compared to 
embryos treated with APAP alone. The free GSH concentration was measured and 
normalised to the untreated embryos for each condition, which are denoted as a 
percentage of the 0 mM treatment group. Embryos treated with NAC alone did not 
have a significantly different amount of free GSH to the untreated wildtype embryo. 
Embryos that were pre-incubated with NAC before the APAP addition, had a decrease 
in free GSH with increasing APAP concentration, however the gradient was smaller in 
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comparison to their counterparts that were treated with APAP only (Figure 6A). The 
concurrent NAC and APAP co-incubation also had a negative correlation between free 
GSH and APAP concentration, but this gradient was (on average), smaller than the 
pre-incubation treatment. Both methods showed a trend where NAC reduced the effect 
of APAP on GSH, but this was not statistically significant. 
Next, 0.5 mM NAC was added to APAP-treated embryos 24h, prior to their harvest at 
stage 45 (n=5) (Figure 6B). The free GSH measured in the embryos treated with NAC 
was (on average), higher than the counterpart embryos treated with the same APAP 
concentration compared with APAP alone. However, the amount of free GSH 
measured in NAC-treated embryos did decrease with increasing APAP concentration, 
though significantly less than in embryos treated with APAP alone. 
Discussion 
To our knowledge, the Xenopus laevis animal model has not been thoroughly 
assessed as a model to predict drug-induced toxicity. To begin to investigate the 
usefulness and limitations of Xenopus laevis embryos in this area, this research 
focused on the response to one known hepatotoxic drug, paracetamol. The results 
generated here suggest that Xenopus could be a suitable model to predict DILI.  
The Xenopus liver has the same cell types as found in humans including hepatocytes, 
stellate cells, Kupffer cells and sinusoidal endothelial cells (29). Similar to vertebrates, 
the liver is derived from the endoderm of the future gut tube, close to where the 
stomach and duodenum will meet (30). By tadpole stage 37-39, the Xenopus liver is a 
sac-like structure, with thick walls that fold inwards and fills the liver cavity with 
hepatocytes. Also at this time, the liver and biliary ductal systems are developing and 
the gall bladder is a thin-walled sac structure (29). At late stage development (stage 
38-45) the Xenopus heart, liver and kidney are functional and adding compounds at 
this stage would assess drug-induced toxicity. Of the key enzymes involved in 
paracetamol metabolism in humans, the Xenopus enzymes of the same name are also 
expressed at stage 38 and stage 45. Including the cytochrome P450 isoform CYP2E1, 
glutathione S-transferase (GST) isoforms P1, M1 and T1, sulphotransferase (SULT) 
isoforms 1A1 and 2A1 and uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A6 
and 1A1 (Supplementary Figure 3).  
It was hypothesised that toxicity assessment using the Xenopus embryos in 
combination with existing in vitro pharmacological cytotoxicity profiling and 
mathematical modelling can provide early in vivo testing without the need for extensive 
early mammalian testing. This will be consistent with the reduction ideology of the 
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National Centre for the Replacement, Refinement and Reduction of Animals in 
research (NC3R). Experiments using Xenopus could help prioritise the lead 
compounds and provide more information than in vitro safety tests. This would flag 
problem compounds before they enter pre-clinical testing in rodents. 
Phenotype and GSH 
The paracetamol concentration range 0-5 mM is consistent with the dose used to 
investigate paracetamol-induced liver injury in zebrafish in the literature. Furthermore, 
the gastrointestinal oedema phenotype in the Xenopus embryos was also observed in 
response to paracetamol in zebrafish larvae (31). Similar to the Xenopus embryos, 
zebrafish larvae were exposed to soluble paracetamol in the media the embryos were 
swimming in. Furthermore, the zebrafish used to model paracetamol-induced 
hepatotoxicity were aged of 72-120 hpf which is close to the Xenopus embryo age 
used in the research presented here (31–34).  
For paracetamol-induced liver injury in humans, the reduced amount of free GSH is 
part of the pathophysiology mechanism as it allows the accumulation of the reactive 
metabolite NAPQI. The reduction of free GSH observed in the Xenopus embryos 
(Figure 2) implies they have generated a small molecule from paracetamol, which 
depletes the free GSH store. The absence of the reduction in the embryos treated for 
only 24h (Figure 2B) indicates the GSH depletion could be time-dependent. Or it could 
be that at stage 38, for the first 24h of the screen, the embryos do not have functional 
enzymes that are responsible for the production of the metabolites. The absence of 
metabolite generation could explain why the amount of free GSH has not been 
reduced. Future work should investigate the metabolic enzyme activity involved with 
Xenopus paracetamol production. Our preliminary work suggests that the embryos do 
generate similar paracetamol metabolites to humans (i.e. APAP-sulphate and APAP-
glucuronide) (data not shown).  
miR-122 
Xenopus miR-122 has the same nucleotide sequence as zebrafish, humans and 
rodents and the WISH results show that miR-122 is liver-specific in the Xenopus, much 
like these animal models as well (20,35,36). The presence of miR-122 in the blood in 
humans is an indication of DILI. The Xenopus embryos have a circulatory system at 
the ages used in this work, but the size of the embryos is too small to be able to easily 
obtain a blood sample, and the volume of blood within the embryo is very little. 
Consequently, in order to measure the expression of miR-122 with paracetamol 
treatment, it was decided to use the tail tissue to represent the blood or circulatory 
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system. The tail contains a good vasculature and the liver tissue is not present in this 
body compartment. Under healthy circumstances there should not be a significant 
amount of miR-122 expression found in the tail. The size of the embryos means 
dissecting the liver alone would be difficult and time consuming. Therefore it was 
decided to dissect the whole gastrointestinal or gut region, including the liver, to 
represent the liver miR-122 expression.  
miR-122 expression was normalised against miR-103 expression in the tissue of the 
embryos. Unlike U6, which is a small nuclear RNA (snRNA) that is traditionally used 
for miRNA quantification in qPCR, miR-103 is not affected by paracetamol treatment 
(25). The increase of miR-122 expression in the tail with increasing paracetamol 
concentration in Figure 4 implies paracetamol-induced liver injury. This is comparable 
to adult zebrafish, which when exposed to a hepatotoxic dose of paracetamol, have a 
significantly high serum miR-122 expression (36).The slight reduction of miR-122 
expression in RNA isolated from gut tissue is potentially indicative of liver damage as 
fragmented WISH miR-122 staining in the liver indicates hepatocyte injury. However, 
there is no linear trend of miR-122 expression in the gut with regards to paracetamol 
concentration. It is hypothesised, this may be because miR-122 expression in the liver 
is so abundant, that a slight depletion cannot be detected. For future work, careful 
histological analysis of the liver to measure the presence of paracetamol-induced liver 
necrosis would need to be carried out to confirm this. 
NAC 
NAC is used to treat patients with a paracetamol overdose. Overall 3 incubation 
conditions were carried out with 0.5 mM NAC and 0-5 mM paracetamol: (1) 2h NAC 
incubation prior to paracetamol addition, (2) concurrent NAC and paracetamol 
treatment, and (3) NAC incubation in paracetamol-treated embryos for 24h prior to 
harvest. Of the 3 conditions performed, the 24h incubation prior to harvest is the most 
clinically relevant to humans. Embryos exposed to 1 mM paracetamol and then 
exposed to 0.5 mM NAC 24h prior to harvest, had an significantly higher amount of 
GSH compared to embryos that were only exposed to 1 mM paracetamol (meanSEM; 
97.19.6 nmol/mg and 54.56.6 nmol/mg respectively). However in all the treatment 
conditions, the amount of free GSH measured is greater in the embryos of the NAC 
treatment group compared with the embryos without NAC, of the same paracetamol 
concentration group. This smaller decline of free GSH with NAC treatment suggests 
the embryos are metabolising paracetamol to generate a small molecule that depletes 
GSH, and that this pathway can be reversed through the administration of NAC. This 
rescue mechanism implies (but cannot confirm) that the reactive metabolite generated 
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in the Xenopus embryos is NAPQI, the same reactive metabolite produced in humans 
and other animal models.  
The results are similar to the NAC response observed in zebrafish paracetamol 
overdose. In adult zebrafish treated with paracetamol, the amount of free GSH 
increased with NAC administration compared to zebrafish treated with paracetamol 
alone (34). Overall, these NAC response results indicate that Xenopus embryos are a 
promising model as they exhibit reactivity to human treatments. 
AMAP: the non-toxic regioisomer of APAP 
AMAP is a controversial, supposedly less toxic positional isomer to paracetamol, which 
has similar therapeutic indications to paracetamol, such as analgesic properties. In 
Xenopus embryos used here, the lack of significant difference between AMAP and 
paracetamol for the depletion of GSH indicates Xenopus could have a similar toxic 
reaction to AMAP as paracetamol. The embryos also have a similar concentration-
dependent survival percentage for AMAP and paracetamol.  This result does not 
necessarily diminish the integrity of the Xenopus as a toxicity prediction model, 
because toxicity associated with AMAP is not consistent across the existing animal 
models in drug development (26). 
Conclusion 
Overall the Xenopus embryo model appears to have the ability to react to paracetamol 
in a dose-dependent manner as shown by looking at GSH levels and also by observing 
the expression of the liver-specific biomarker miR-122 in the embryo. This is 
comparable to research undertaken using zebrafish (31–34). The depletion of GSH 
with paracetamol treatment suggests the Xenopus embryo metabolic pathway is 
similar to that observed in humans and rodent paracetamol-induced liver injury models. 
To our knowledge, GSH reduction has not been measured in the zebrafish 
paracetamol-induced hepatotoxicity model. Going forward it would be interesting to 
confirm the mechanism of toxicity using a CYP450 inhibitor that is valid for Xenopus. 
Furthermore, the CYP450 isoform that could be involved in the Xenopus metabolism 
of paracetamol should be determined. Although the dominant isoform in humans that 
generates the reactive metabolite NAPQI is the CYP2E1, in zebrafish the CYP3A65 
isoform is predominantly responsible for NAPQI generation (37). At stage 38 to stage 
45, the Xenopus embryos express CYP2D6 and CYP3A4 as well as CYP2E1. In 
humans CYP2D6 and CYP3A4 are responsible for over 50 % of all drugs (38).  In 
summary, these results represent the initial steps towards determining the advantages 
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and limitations of the Xenopus embryo model as a predictive tool for DILI, and pave 
the way for future assessment of the value of Xenopus as an efficient and effective in 
vivo toxicity model for other organ systems.  
 
Methods 
All experiments were performed in compliance with the relevant laws and institutional 
guidelines at the University of East Anglia. This research has been approved by the 
local ethical review committee according to UK Home Office regulations. Xenopus 
embryo stages were identified according to Nieuwkoop & Faber (1994) (30). 
 
Xenopus laevis embryos develop at a rate that is proportional to the temperature at 
which they are incubated. Consequently, unlike the zebrafish, the age of a Xenopus 
embryo cannot be given in hours post fertilisation (hpf), instead, the age can be 
identified using the developmental stages set out by Nieuwkoop and Faber (these can 
also be found on the NIH-funded website xenbase.org) (30).  At 25°C, a Xenopus 
embryo can develop into an adult in 12 months, this is the temperature that elicits the 
fastest development rate. At <12°C the embryos will die however, between 12°C and 
25°C, the embryos will develop at a rate proportional to the temperature. An incubation 
temperature of 23°C was used for all of the following experiments. 
Embryo fixing 
Once the embryos reached their desired stage they were fixed using MEMFA (3.7% 
(v/v) formaldehyde, 1X MEM salts (0.1 M MOPS, 2 mM EGTA, 1 mM MgSO4, pH7.4) 
made up with dH2O. They were then dehydrated in 100 % ethanol (EtOH) and stored 
at -20°C. 
RNA isolation and cDNA synthesis 
After incubation until the stage required, 10 embryos were frozen in liquid nitrogen for 
at least 2 h. mRNA was isolated using the trizol method, miRNA was isolated using 
the miRCURYTM RNA Isolation (for tissue) kit according to manufacturer’s instructions. 
For miRNA, cDNA was generated using the Universal cDNA synthesis kit II (Exiqon). 
qRT-PCR 
The reaction was performed in MicroAmp optical 96 well plate (Applied Biosystems)., 
miRCURYTM LNA PCR Primer mix (Exiqon) or 10 μM MRP2 primer and SYBR® Green 
PCR Master Mix (Applied Biosystems). A 7500 real-time PCR instrument (Applied 
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Biosystems) was used under the following conditions. Samples were plated in 
triplicates (technical replicates). Samples derived from embryos produced from 
different mothers were the biological replicates. 
Wholemount in situ hybridisation (WISH) 
DIG labelled probes were synthetised with a Digoxigenin (DIG) labeled UTPs (Roche) 
and purified using Illustra MicroSpin G-50 Columns (GE healthcare life sciences) 
according to manufacturer’s instructions. Micro-RNA probes were obtained from 
Exiqon. WISH was carried out as previously described (20,39) 
Paracetamol treatment 
Paracetamol (Sigma, UK) was dissolved in 0.1X MMR alone. Embryo age was 
determined according to Nieuwkoop & Faber (1994) (30). For 1 biological replicate 
(n=1), we used 7 embryos for each drug concentration. Consequently 5 biological 
replicates (n=5) used a total of 35 embryos. 1 biological replicate is defined as using 1 
adult frog mother. In other words, a result generated from embryos that have the same 
mother, was only counted as 1 biological replicate. 
The preparation of samples for the measurement of miR-122 
expression using qRT-PCR  
Stage 38 embryos were treated with paracetamol as described above until stage 45. 
At stage 45, the embryos put into 0.5 mg/mL tricaine (0.1X MMR) and incubated at 
23°C for 1 h. Embryos were dissected into tail and gut tissue using a simple razor 
blade. The dissection technique was confirmed by analyzing the expression of the 
liver-specific marker AMBP. AMBP was expressed in the gut tissue dissected but not 
in the tail tissue. 
N-acetyl cysteine (NAC) and paracetamol 
Pre-incubation 
Stage 38 embryos were exposed to a final concentration of 0.5 mM NAC at 23°C for 2 
h prior to paracetamol. This was incubated for a further 70 h, until the embryos were 
stage 45 at 23°C. The embryos were processed with the GSH assay method. 
Concurrent treatment 
Stage 38 embryos were exposed to a final concentration of 0.5 mM NAC and a 
paracetamol concentration within the range 0-5 mM paracetamol at 23°C for 72 h until 
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the embryos were stage 45. The embryos were processed with the GSH assay 
method. 
24 h NAC treatment prior to harvest 
Stage 38 embryos were exposed to paracetamol within the range 0-5 mM at 23°C for 
48 h. At 48 h we added NAC to a final concentration of 0.5 mM and this was further 
incubated for 24 h at 23°C until the embryos were stage 45. 
 
All the embryos were processed with the GSH assay method at stage 45. 
Measuring free GSH 
Sample preparation 
At the end of the incubation period, embryos that were treated with the same conditions 
were pooled. As much as possible, the incubation solution was removed and the 
embryos were homogenized. The amount of free GSH was measured in the 
supernatant using a GloMax® Explorer System spectrophotometer (Promega) and 
quantified using the Bradford assay. 
Statistical analysis 
Statistical tests were carried out using GraphPad Prism 6.0 software. An ordinary one-
way ANOVA was used for investigating the difference of the treated groups compared 
to the untreated embryos and Mann-Whitney non-parametric tests were used to 
compare unpaired treatment groups.  
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FIGURE LEGENDS 
 
Figure 1: Paracetamol exposure dose-response phenotype 
Xenopus laevis embryos were exposed to a paracetamol concentration in the range 0-
5 mM (n=4). The embryos were exposed to paracetamol from stage 38 and harvested 
at stage 45. Phenotypes include wildtype (A), damaged tail (B), oedema (C), abnormal 
gut (D) and bent tail (E). The surviving embryos at stage 45 were photographed and 
the different phenotypes found for each paracetamol concentration were calculated as 
a percentage of total embryos tested (F). Where possible, the embryos were 
photographed to show the lateral view and the ventral view. Scale bar represents 1 
mm. 
 
Figure 2: The amount of free GSH inside Xenopus embryos treated with 
paracetamol. 
Xenopus laevis embryos were exposed to 0-5 mM paracetamol from the age of stage 
38, and harvested at stage 45 (A, n=10) or at stage 41 (B, n=3). The amount of free 
GSH (nmol/mL) was measured inside the embryos and normalised to the amount of 
protein (mg/mL). An ordinary one-way ANOVA compared each exposure group to the 
group exposed to Xenopus media alone (0 mM). For the embryos exposed until stage 
45 (A), the amount of free GSH for 3, 3.5, 4 and 4.5 mM paracetamol exposure groups 
was statistically significant compared to the group exposed to Xenopus media only 
(P<0.05). The 5 mM paracetamol exposure group was also statistically significantly 
different (P<0.01). There was no significant difference between treated and untreated 
embryos that were harvested at stage 41 (B). 
 
Figure 3: Wholemount in situ hybridisation (WISH) for liver markers. 
WISH assay for Alpha-1-Microgobulin/Bikunin Precursor (AMBP) (A) and miR-122 (B) 
at stage 38 (Ai and Bi) and stage 45 (Aii and Bii). The stage 38 embryos are shown in 
lateral view and the stage 45 embryos are shown ventrally. The specific purple WISH 
stain is indicated with an arrow. These embryos are representatives of the typical 
expression patterns seen (n=10). Scale bar represents 1 mm. 
 
Figure 4 Expression of miR-122 in paracetamol-treated embryos. 
Stage 38 embryos were exposed to paracetamol (0-5 mM) and harvested at stage 45. 
The expression of miR-122 in the gut (purple) and tail (red) was measured using qRT-
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PCR (log (fold change ± SEM)) and normalised to embryos exposed to Xenopus media 
only (0 mM). The statistically significant difference of miR-122 expression between 
tissues from embryos treated with the same paracetamol concentration was measured 
using the Mann-Whitney test (P<0.05) (n=5). 
 
Figure 5: The amount of free GSH inside Xenopus embryos treated with 
paracetamol (APAP) or N-acetyl-meta-aminophenol (AMAP). 
Xenopus laevis embryos were exposed to up to 5 mM paracetamol (APAP) or up to 5 
mM N-acetyl-meta-aminophenol (AMAP) from the age of stage 38 and harvested at 
stage 45 (n=3). The amount of free GSH (nmol/mL) was measured inside the embryos 
and normalised to the amount of protein (mg/mL). There was no significant difference 
between embryos treated with the same concentration of APAP and AMAP. 
 
Figure 6: Free GSH in embryos treated with paracetamol and N-acetyl cysteine 
(NAC). 
Stage 38 embryos were exposed to paracetamol (up to 5 mM) for 72h with or without 
the addition of 0.5 mM NAC, they were harvested at stage 45. For the initial 
experiments (A) there were 3 conditions: exposure to paracetamol alone (blue), 2h 
incubation with NAC prior to the addition of paracetamol (pink) and concurrent 
treatment with NAC and paracetamol (yellow) (n=10). The embryos were also exposed 
to APAP from stage 38 and then with NAC for 24h prior to harvest (green) at stage 45, 
a 72h incubation period, or with paracetamol alone (blue) (B) (n=5). The amount of 
free GSH inside the embryos was measured and normalised to the amount of protein. 
This value was then normalised to the embryos exposed to Xenopus media alone (0 
mM). The amount of free GSH measured was calculated as a percentage of the 0 mM 
paracetamol exposure group (±SEM). A multiple comparison 2 way ANOVA was 
performed to measure the statistical significance between groups of them same 
paracetamol exposure, with and without additional NAC exposure (P<0.05). 
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